Skip to main content
SpringerLink
Log in

Valbenazine in tardive dyskinesia: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Valbenazine (Ingrezza®) is an orally bioavailable, selective and reversible vesicular monoamine transporter 2 (VMAT2) inhibitor that is indicated for the once-daily treatment of adults with tardive dyskinesia (TD) in the USA. By inhibiting VMAT2, thereby interfering with the presynaptic uptake and storage of dopamine and other monoamines, valbenazine is thought to counteract the heightened postsynaptic dopaminergic activity that is believed to cause TD. In adults with dopamine-receptor blocking agent-induced TD and underlying schizophrenia, schizoaffective disorder or mood disorder, valbenazine was associated with rapid, significant and sustained on-treatment improvements in TD severity relative to placebo. Somnolence is the most common treatment-emergent adverse event associated with valbenazine and, importantly, depression and extrapyramidal symptoms have not been associated with its use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1.

    PubMed Central  Google Scholar 

  2. Jones BD. Long-term neuroleptic toxicity and mood: blurring of diagnostic boundaries. In: Williams R, Dalby JT, editors. Depression in schizophrenics. Boston: Springer; 1989. p. 203–13.

    Chapter  Google Scholar 

  3. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–76.

    Article  PubMed  CAS  Google Scholar 

  4. Goel S, Ondo W. Tardive dyskinesia. In: Falup-Pecurariu C, Ferreira J, Martinez-Martin P, Chaudhuri KR, editors. Movement disorders curricula. Vienna: Springer; 2017. p. 283–9.

    Chapter  Google Scholar 

  5. Aia PG, Revuelta GJ, Cloud LJ, et al. Tardive dyskinesia. Curr Treat Options Neurol. 2011;13(3):231–41.

    Article  PubMed  Google Scholar 

  6. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23(8):649–59.

    PubMed  Google Scholar 

  7. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–9.

    Article  PubMed  Google Scholar 

  8. Kim ES. Valbenazine: first global approval. Drugs. 2017;77(10):1123–9.

    Article  PubMed  CAS  Google Scholar 

  9. Ingrezza® (valbenazine) capsules, for oral use: US prescribing information. San Diego: Neurocrine Biosciences, Inc.; 2017.

  10. Grigoriadis DE, Smith E, Hoare SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454–61.

    Article  PubMed  CAS  Google Scholar 

  11. Ingrezza (valbenazine) capsules: medical review(s) [reference ID: 4079314]. Silver Spring (MD): US FDA Center for Drug Evaluation and Research; 2017.

  12. Neurocrine Biosciences. Neurocrine announces phase IIb results of VMAT2 inhibitor NBI-98854 for treatment of tardive dyskinesia [media release]. http://www.neurocrine.com/. Accessed 9 Sep 2013.

  13. O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–84.

    Article  PubMed  Google Scholar 

  15. Ingrezza (valbenazine) capsules: summary review (reference ID: 4082860). Silver Spring (MD): US FDA Center for Drug Evaluation and Research; 2017.

  16. Factor SA, Remington G, Comella C, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78(9):1344–50

    Article  PubMed  Google Scholar 

  17. Kane JM, Correll CU, Liang GS, et al. Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder. Psychopharmacol Bull. 2017;47(3):69–76.

    PubMed  PubMed Central  Google Scholar 

  18. Correll CU, Josiassen RC, Liang GS, et al. Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and mood disorder. Psychopharmacol Bull. 2017;47(3):53–60.

    PubMed  PubMed Central  Google Scholar 

  19. Thai-Cuarto D, O’Brien CF, Jimenez R, et al. Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials. Drug Saf. 2017. https://doi.org/10.1007/s40264-017-0623-1 [Epub ahead of print].

    Article  PubMed Central  Google Scholar 

  20. Remington G, Factor S, Comella C, et al. Safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia: results of long-term exposure data from three studies [abstract no. P2.017]. Neurology. 2017;88(16 Suppl).

  21. Josiassen RC, Kane JM, Liang GS, et al. Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull. 2017;47(3):61–8.

    PubMed  PubMed Central  Google Scholar 

  22. Austedo® (deutetrabenazine) tablets: US prescribing information. North Wales (PA): Teva Pharmaceuticals USA, Inc.; 2017.

  23. Josiassen RCJ, Filmyer DM, Gillean J, et al. Successful treatment of severe tardive dyskinesia with valbenazine, including a patient’s perspective. Am J Case Rep. 2017; 18:1185–9. https://www.amjcaserep.com/download/index/idArt/906454

Download references

Acknowledgements

The manuscript was updated from Drugs 2017;77(10):1123–29 [8], and was reviewed by: L.J. Cloud, Department of Neurology, School of Medicine, Virginia Commonwealth University, Richmond (VA), USA; J.H. Friedman, Movement Disorders Program, Butler Hospital, and Department of Neurology, Warren Alpert Medical School of Brown University, Providence (RI), USA; R.C. Josiassen, Translational Neuroscience LCC, Conshohocken (PA),USA; M. Solmi, Psychiatry Unit, Neurosciences Department, University of Padua, Padua, Italy. During the peer review process, the manufacturer of valbenazine was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Funding

The preparation of this review was not supported by any external funding.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Esther S. Kim & Katherine A. Lyseng-Williamson

Authors
  1. Esther S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Conflicts of interest

E.S. Kim and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Additional information about this Adis Drug Review can be found here http://www.medengine.com/Redeem/C9ECF060386A50C9.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, E.S., Lyseng-Williamson, K.A. Valbenazine in tardive dyskinesia: a profile of its use. Drugs Ther Perspect 34, 99–104 (2018). https://doi.org/10.1007/s40267-018-0479-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0479-1

Search

Navigation